Closed on Tuesday, 20 August 2013, 05:00pm (AEDT). Submissions are no longer being accepted.
Advice on use of the PSA test to detect prostate cancer can be conflicting and confusing. On one hand, prostate cancer may be detected at an early stage where treatment may be simpler and more effective. On the other hand, the potential harms of a false test result, overdiagnosis, or overtreatment may outweigh any benefit.
Prior to a PSA test being ordered and gaining a man’s consent to undergo a test, men should be fully informed of both the benefits and harms of testing and subsequent investigations and treatments.
NHMRC has undertaken a review of the scientific evidence.
PSA testing for Prostate Cancer in Asymptomatic Men: Information for Health Practitioners provides a summary of this evidence for health practitioners. By providing balanced information on both the potential benefits and harms of PSA testing in asymptomatic men, the document aims to assist health practitioners in their discussions with men and their families.
You are invited to make a submission on the draft.
The evidence underpinning the Information Document has been sourced from NHMRC’s review of the scientific evidence, namely the PSA testing in asymptomatic men: Evidence Evaluation Report; and PSA testing in asymptomatic men: Technical Report. Note: these reports are provided for background only- they are not part of this public consultation.
Please note that no extensions will be given.